PT - JOURNAL ARTICLE AU - Rand A. Alattar AU - Shiema Abdalla AU - Tasneem A.K. Abdallah AU - Rashid Kazman AU - Aseelah Qadmour AU - Tawheeda B. H. Ibrahim AU - Bassem Alhariri AU - Shahd H. Shaar AU - Abeer Bajwa AU - Abeir B. Alimam AU - Rabia Qazi AU - Fatma Ben Abid AU - Joanne Daghfal AU - Ali M. Eldeeb AU - Kinda Shukri AU - Ahmed Elsayed AU - Fatima Rustom AU - Musaed Alsamawi AU - Alaaeldin Abdelmajid AU - Miguel A. P. Basulto AU - Armando A. R. Cobian AU - Mohamed Abukhattab AU - Muna A. Almaslamani AU - Abdullatif Alkhal AU - Ali S. Omrani TI - Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study AID - 10.1101/2021.11.29.21267042 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.29.21267042 4099 - http://medrxiv.org/content/early/2021/11/30/2021.11.29.21267042.short 4100 - http://medrxiv.org/content/early/2021/11/30/2021.11.29.21267042.full AB - Background We investigated clinical outcomes of favipiravir in patients with COVID-19 pneumonia.Methods Patients who between 23 May 2020 and 18 July 2020 received ≥24 hours of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. Cox regression was used to examine associations with the primary endpoint.Results The unmatched cohort included 1,493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Favipiravir was started within a median of 5 days from symptoms onset. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P <0.001). In the adjusted Cox proportional hazards model, favipiravir therapy was not associated 28-day clinical improvement (adjusted hazard ratio 0.978, 95% confidence interval 0.862 –1.109, P 0.726). Adverse events were common in both groups, but the 93.9% were Grades 1–3.Conclusion Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:approved by the Institutional Review Board at Hamad Medical Corporation (MRC-01-20-994) with a waiver of informed consentI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding authorALTalanine transferaseALPalkaline phosphataseASTaspartate transferaseCOVID-19coronavirus disease 2019CRPC-reactive proteinCTCAECommon Terminology Criteria for Adverse EventsECMOextracorporeal membrane oxygenationEC50half maximal effective concentrationHFNOhigh-flow nasal oxygenHMCHamad Medical CorporationIMVinvasive mechanical ventilationIQRinterquartile rangesLPV/rlopinavir-ritonavirNIVnon-invasive ventilationQTccorrected QT intervalRT-PCRreal-time polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus